TY - JOUR
T1 - Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer
AU - Wang, Lisha
AU - Ren, Fei
AU - Wang, Qifeng
AU - Baldridge, Lee Ann
AU - Monn, M. Francesca
AU - Fisher, Kurt W.
AU - Sheng, Weiqi
AU - Zhou, Xiaoyan
AU - Du, Xiang
AU - Cheng, Liang
N1 - Publisher Copyright:
© 2016, Springer International Publishing Switzerland.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Introduction: The significance of programmed death ligand 1 (PD-L1) expression in the prognosis of patients with colorectal cancer remains to be determined. Methods: We assessed the levels of PD-L1 expression in tumor-infiltrating immune cells as well as tumor cells, and evaluated the association between PD-L1 expression and clinical outcome in 262 colorectal cancer patients. Results: In univariate analysis, TNM stage (p < 0.001), PD-L1 expression in tumor-infiltrating immune cells (p = 0.016), tumor location (p = 0.033), and tumor size (p = 0.019) were associated with survival. In multivariate analysis, PD-L1 expression in tumor infiltrating immune cells and TNM stage were independent prognostic factors (HR 1.83, 95 % CI 1.09–3.05, p = 0.021; HR 2.49, 95 % CI 1.51–4.12, p < 0.001, respectively). Eight percent of patients had positive PD-L1 expression in tumor cells. In contrast, PD-L1 expression in tumor cells was not significantly associated with patient clinical outcome. Conclusions: Our data indicate that PD-L1 status in tumor-infiltrating immune cells is a significant prognostic factor in colorectal cancer patients. There is a need for randomized studies that evaluate the role of PD-L1 expression in colorectal cancer in treatment decision protocols for novel immunotherapy.
AB - Introduction: The significance of programmed death ligand 1 (PD-L1) expression in the prognosis of patients with colorectal cancer remains to be determined. Methods: We assessed the levels of PD-L1 expression in tumor-infiltrating immune cells as well as tumor cells, and evaluated the association between PD-L1 expression and clinical outcome in 262 colorectal cancer patients. Results: In univariate analysis, TNM stage (p < 0.001), PD-L1 expression in tumor-infiltrating immune cells (p = 0.016), tumor location (p = 0.033), and tumor size (p = 0.019) were associated with survival. In multivariate analysis, PD-L1 expression in tumor infiltrating immune cells and TNM stage were independent prognostic factors (HR 1.83, 95 % CI 1.09–3.05, p = 0.021; HR 2.49, 95 % CI 1.51–4.12, p < 0.001, respectively). Eight percent of patients had positive PD-L1 expression in tumor cells. In contrast, PD-L1 expression in tumor cells was not significantly associated with patient clinical outcome. Conclusions: Our data indicate that PD-L1 status in tumor-infiltrating immune cells is a significant prognostic factor in colorectal cancer patients. There is a need for randomized studies that evaluate the role of PD-L1 expression in colorectal cancer in treatment decision protocols for novel immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84958739399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958739399&partnerID=8YFLogxK
U2 - 10.1007/s40291-016-0188-1
DO - 10.1007/s40291-016-0188-1
M3 - Article
C2 - 26891728
AN - SCOPUS:84958739399
SN - 1177-1062
VL - 20
SP - 175
EP - 181
JO - Molecular Diagnosis and Therapy
JF - Molecular Diagnosis and Therapy
IS - 2
ER -